Summary
Signal counts
Assets tracked: 2
Watchlist assets: 1
Registry stop assets: 1
Sponsor overview
Shandong Cancer Hospital and Institute
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06532539 | https://clinicaltrials.gov/study/NCT03557411 | https://clinicaltrials.gov/study/NCT03645876
Assets
Linked programs
- Paclitaxel and Cisplatin: Low Signal (1/5)
- SHR-1210: Registry Stop Signal (5/5)